Skip to main content

Advertisement

SpringerLink
Log in

Natural history of hypertrophic cardiomyopathy

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Hypertrophic cardiomyopathy is a disease of the cardiac sarcomere and is the most common inherited cardiovascular disorder affecting up to 1 in 500 people in the general population. The disease is typified by variable clinical penetrance and heterogeneous clinical expression, resulting in a wide range of clinical manifestations. Most patients have few if any symptoms and a relatively benign clinical course. A minority are at risk of serious complications including ventricular arrhythmia, sudden death, thromboembolism, congestive cardiac failure, heart block, and infective endocarditis. This article reviews the natural history of the disease, with particular emphasis on lessons learned from recent genetic studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Maron BJ, Gardin JM, Flack JM, et al.: Prevalence of hypertrophic cardiomyopathy in a population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92:785–789.

    PubMed  CAS  Google Scholar 

  2. Savage DD, Castelli WP, Abbott RD, et al.: Hypertrophic cardiomyopathy and its markers in the general population: the great masquerader revisited: the Framingham Study. J Cardiovasc Ultrason 1983, 2:41–47.

    Google Scholar 

  3. Hada Y, Sakamoto T, Amano K, et al.: Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 1987, 59:183–184.

    Article  PubMed  CAS  Google Scholar 

  4. Codd MB, Sugrue DD, Gersh BJ, Melton LJ: Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy: a population based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989, 80:564–572.

    PubMed  CAS  Google Scholar 

  5. Maron BJ, Peterson EE, Maron MS, Peterson JE: Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol 1994, 73:577–580.

    Article  PubMed  CAS  Google Scholar 

  6. Evans W: Familial cardiomegaly. Br Heart J 1949, 11:68–82.

    CAS  PubMed  Google Scholar 

  7. Teare D: Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958, 20:1–8.

    PubMed  CAS  Google Scholar 

  8. Geisterfer-Lowrance AAT, Kass S, Tanigawa G, et al.: A molecular basis for familial hypertrophic cardiomyopathy: a β-cardiac myosin heavy chain gene missense mutation. Cell 1990, 62:999–1006.

    Article  PubMed  CAS  Google Scholar 

  9. Thierfelder L, Watkins H, MacRae C, et al.: Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994, 77:701–712.

    Article  PubMed  Google Scholar 

  10. Watkins H, Conner D, Thierfelder L, et al.: Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:434–437.

    Article  PubMed  CAS  Google Scholar 

  11. Bonne G, Carrier L, Bercovici J, et al.: Cardiac myosin binding protein C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:438–440.

    Article  PubMed  CAS  Google Scholar 

  12. Kimura A, Harada H, Park J-E et al.: Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997, 16:379–382.

    Article  PubMed  CAS  Google Scholar 

  13. Morgensen J, Klausen IC, Pedersen AK, et al.: Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999, 103:R39–43. This is the first study to demonstrate that mutations in alpha cardiac actin can cause hypertrophic cardiomyopathy.

    Google Scholar 

  14. Poetter K, Jiang H, Hassanzadeh S, et al.: Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996, 13:63–69.

    Article  PubMed  CAS  Google Scholar 

  15. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775–785.

    Article  PubMed  CAS  Google Scholar 

  16. Redwood CS, Moolman-Smook JC, Watkins H: Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999, 44:20–36.

    Article  PubMed  CAS  Google Scholar 

  17. Maron BJ, Spirito P, Wesley Y, Arce J: Development or progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy: identification by two-dimensional echocardiography. N Engl J Med 1986, 315:610–614.

    Article  PubMed  CAS  Google Scholar 

  18. Faye WP, Taliercio CP, Ilstrup DM, et al.: Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990, 16:821–826.

    Article  Google Scholar 

  19. Lewis JF, Maron BJ: Clinical and morphology expression of hypertrophic cardiomyopathy in patients Š 65 years of age. Am J Cardiol 1994, 73:1105–1111.

    Article  PubMed  CAS  Google Scholar 

  20. Charron P, Dubourg O, Desnos M, et al.: Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin binding protein C gene. Circulation 1998, 97:2230–2236. This paper along with that by Niimura et al. [21] demonstrate that the prevalence of hypertrophy in families with mutations in the cardiac myosin binding protein-C gene increases beyond the second decade. The implication of these two studies is that some cases of apparent late-onset hypertrophic cardiomyopathy are caused by delayed expression of sarcomeric protein gene mutations.

    PubMed  CAS  Google Scholar 

  21. Niimura H, Bachinski LL, Sangwatanaroj S, et al.: Mutations in the gene for cardiac myosin-binding protein C and late onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248–1257. This paper along with that by Charron et al. [20] demonstrate that the prevalence of hypertrophy in families with mutations in the cardiac myosin binding protein-C gene increases beyond the second decade. The implication of these two studies is that some cases of apparent late-onset hypertrophic cardiomyopathy are caused by delayed expression of sarcomeric protein gene mutations.

    Article  PubMed  CAS  Google Scholar 

  22. Elliott PM, D'Cruz L, McKenna WJ: Late-onset hypertrophic cardiomyopathy caused by a mutation in the troponin T gene. N Engl J Med 1999, 341:1855. First report of a troponin T gene mutation causing hypertrophic cardiomyopathy.

    Article  PubMed  CAS  Google Scholar 

  23. Chikamori T, Counihan PJ, Doi YL, et al.: Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol 1992, 19:507–512.

    Article  PubMed  CAS  Google Scholar 

  24. Jones S, Elliott PM, Sharma S, et al.: Cardiopulmonary response to exercise in patients with hypertrophic cardiomyopathy. Heart 1998, 80:60–67.

    PubMed  CAS  Google Scholar 

  25. Shah PM, Adelman AG, Wigle ED, et al.: The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res 1974, 35(suppl 2):179–195.

    PubMed  Google Scholar 

  26. Loogen F, Kuhn H, Gietzen F, et al.: Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J 1983, 4 (suppl F):145–153.

    PubMed  Google Scholar 

  27. McKenna WJ, Deanfield J, Faruqui A, et al.: Prognosis in hypertrophic cardiomyopathy. Role of age and clinical, electrocardiographic and haemodynamic features. Am J Cardiol 1981, 47:532–538.

    Article  PubMed  CAS  Google Scholar 

  28. Koga Y, Itaya K, Toshima H: Prognosis in hypertrophic cardiomyopathy. Am Heart J 1984, 108:351–359.

    Article  PubMed  CAS  Google Scholar 

  29. Shapiro LM, Zezulka A: Hypertrophic cardiomyopathy: a common disease with a good prognosis. five year experience of a district general hospital. Br Heart J 1983, 50:530–533.

    PubMed  CAS  Google Scholar 

  30. Spirito P, Chiarella F, Carratino L et al.: Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989, 320:749–755.

    Article  PubMed  CAS  Google Scholar 

  31. Romeo F, Pelliccia F, Cristofani R, et al.: Hypertrophic cardiomyopathy: Is a left ventricular outflow tract gradient a major prognostic determinant? Eur Heart J 1990, 11:233–240.

    PubMed  CAS  Google Scholar 

  32. Kofflard MJ, Waldstein DJ, Vos J, ten Cate F: Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993, 72:939–943.

    Article  PubMed  CAS  Google Scholar 

  33. Cecchi F, Olivotto I, Montereggi A, et al.: Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995, 26:1529–1536.

    Article  PubMed  CAS  Google Scholar 

  34. Cannan CR, Reeder GS, Bailey KR, et al.: Natural history of hypertrophic cardiomyopathy. A population based study, 1976 through 1990. Circulation 1995, 92:2488–2495.

    PubMed  CAS  Google Scholar 

  35. Maron BJ, Casey SA, Poliac LC, et al.: Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999, 281:650–655. Large series from a regional population describing natural history of disease.

    Article  PubMed  CAS  Google Scholar 

  36. Maron BJ, Roberts WC: Quantitative analysis of cardiac muscle cell disorganisation in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 1979, 59:689–706.

    PubMed  CAS  Google Scholar 

  37. Factor SM, Butany J, Sole MJ, et al.: Pathological fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1991, 17:1343–1351.

    Article  PubMed  CAS  Google Scholar 

  38. Davies MJ, McKenna WJ: Hypertrophic cardiomyopathy: pathology and pathogenesis. Histopathology 1995, 26:493–500.

    Article  PubMed  CAS  Google Scholar 

  39. Elliott PM, Sharma S, Varnava A, et al.: Survival Following Cardiac Arrest or Sustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 1999, 33:1596–1601. Study describing outcome in patients that have survived cardiac arrest. The study indicates that ICD therapy is the treatment of choice in patients that have survived a cardiac arrest.

    Article  PubMed  CAS  Google Scholar 

  40. Cannon RO, Dilsizian V, O'Gara P, et al.: Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991, 83:1660–1667.

    PubMed  Google Scholar 

  41. Camici P, Chiriatti G, Lorenzoni R, et al.: Coronary vasodilatation is impaired in both hypertrophied and non hypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with Nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991, 17:879–886.

    Article  PubMed  CAS  Google Scholar 

  42. Elliott PM, Rosano GMC, Gill JS, et al.: Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy. Heart 1996, 75:179–183.

    PubMed  CAS  Google Scholar 

  43. Gibson DG, Sanderson JE, Traill TA, et al.: Regional left ventricular wall movement in hypertrophic cardiomyopathy. Br Heart J 1978, 40:1327–1333.

    PubMed  CAS  Google Scholar 

  44. Spirito P, Maron BJ, Bonow RO, Epstein SE: Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987, 60:123–129.

    Article  PubMed  CAS  Google Scholar 

  45. Hunter JJ, Chien KR: Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999, 341:1276.

    Article  PubMed  CAS  Google Scholar 

  46. Pak P, Maughan L, Baughman KL, Kass DA: Marked discordance between dynamic and passive diastolic pressure — volume relations in idiopathic hypertrophic cardiomyopathy. Circulation 1996, 94:52–60.

    PubMed  CAS  Google Scholar 

  47. Varnava A, Baboonian C, Davison F, et al.: A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart 1999, 82:621–624. This study demonstrates that troponin T gene mutations can produce a clinical picture of restrictive rather than hypertrophic cardiomyopathy.

    PubMed  CAS  Google Scholar 

  48. Robinson K, Frenneaux MP, Stockins B, et al.: Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study. J Am Coll Cardiol 1990, 15:1279–1285.

    Article  PubMed  CAS  Google Scholar 

  49. Spirito P, Rapezzi C, Bellone P, et al.: Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999, 99:2132–2137. This is the largest series examining the prevalence of and risk factors for infective endocarditis in patients with hypertrophic cardiomyopathy.

    PubMed  CAS  Google Scholar 

  50. Cecchi F, Olivotto I, Montereggi A, et al.: Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1999, 79:331–336. Large regional population describing experience with amiodarone therapy.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiological Sciences, St. George's Hospital Medical School, Cranmer Terrace, SW17 0RE, London, UK

    Perry M. Elliott MBBS, MRCP

Authors
  1. Perry M. Elliott MBBS, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elliott, P.M. Natural history of hypertrophic cardiomyopathy. Curr Cardiol Rep 2, 141–147 (2000). https://doi.org/10.1007/s11886-000-0011-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-000-0011-8

Keywords

Search

Navigation